Cim Investment Management Inc. Purchases 1,445 Shares of DexCom, Inc. (NASDAQ:DXCM)

Cim Investment Management Inc. lifted its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 65.2% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 3,662 shares of the medical device company’s stock after purchasing an additional 1,445 shares during the period. DexCom accounts for approximately 0.5% of Cim Investment Management Inc.’s investment portfolio, making the stock its 26th biggest holding. Cim Investment Management Inc.’s holdings in DexCom were worth $1,564,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the company. Lone Pine Capital LLC increased its stake in shares of DexCom by 4.6% during the first quarter. Lone Pine Capital LLC now owns 2,373,148 shares of the medical device company’s stock worth $852,886,000 after purchasing an additional 105,339 shares during the period. Artisan Partners Limited Partnership increased its stake in DexCom by 0.3% during the 2nd quarter. Artisan Partners Limited Partnership now owns 1,974,019 shares of the medical device company’s stock worth $842,906,000 after acquiring an additional 6,190 shares during the period. Janus Henderson Group PLC increased its stake in DexCom by 201.4% during the 1st quarter. Janus Henderson Group PLC now owns 1,868,977 shares of the medical device company’s stock worth $671,700,000 after acquiring an additional 1,248,830 shares during the period. Geode Capital Management LLC increased its stake in DexCom by 16.9% during the 2nd quarter. Geode Capital Management LLC now owns 1,748,126 shares of the medical device company’s stock worth $744,433,000 after acquiring an additional 252,773 shares during the period. Finally, Nuveen Asset Management LLC boosted its holdings in shares of DexCom by 22.0% in the 1st quarter. Nuveen Asset Management LLC now owns 1,288,354 shares of the medical device company’s stock valued at $463,021,000 after purchasing an additional 232,083 shares in the last quarter. Institutional investors own 96.29% of the company’s stock.

In related news, Director Mark G. Foletta sold 500 shares of the stock in a transaction on Friday, October 1st. The stock was sold at an average price of $543.09, for a total value of $271,545.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Chad Patterson sold 291 shares of the stock in a transaction on Thursday, September 9th. The shares were sold at an average price of $541.37, for a total value of $157,538.67. The disclosure for this sale can be found here. In the last ninety days, insiders sold 43,766 shares of company stock worth $22,883,487. Insiders own 0.52% of the company’s stock.

DXCM has been the topic of several recent research reports. SVB Leerink lifted their target price on DexCom from $485.00 to $500.00 and gave the stock an “outperform” rating in a report on Friday, July 30th. Citigroup lifted their price objective on DexCom from $530.00 to $630.00 and gave the stock a “buy” rating in a research report on Friday, October 1st. Stephens lifted their price objective on DexCom from $468.00 to $546.00 and gave the stock an “overweight” rating in a research report on Friday, July 30th. Canaccord Genuity lifted their price objective on DexCom from $455.00 to $500.00 and gave the stock a “buy” rating in a research report on Friday, July 30th. Finally, Wells Fargo & Company boosted their target price on DexCom from $380.00 to $475.00 and gave the company an “equal weight” rating in a research report on Friday, July 30th. Two research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $515.13.

DXCM stock traded up $10.59 during mid-day trading on Thursday, reaching $558.64. 13,962 shares of the company traded hands, compared to its average volume of 743,023. The stock has a market cap of $54.05 billion, a price-to-earnings ratio of 104.39, a P/E/G ratio of 14.59 and a beta of 0.77. The company has a quick ratio of 5.25, a current ratio of 5.78 and a debt-to-equity ratio of 0.86. DexCom, Inc. has a fifty-two week low of $305.63 and a fifty-two week high of $579.00. The firm’s 50 day moving average price is $533.80 and its 200 day moving average price is $448.21.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Thursday, July 29th. The medical device company reported $0.76 EPS for the quarter, beating the consensus estimate of $0.43 by $0.33. DexCom had a return on equity of 16.17% and a net margin of 24.45%. The business had revenue of $595.10 million for the quarter, compared to the consensus estimate of $548.02 million. On average, analysts anticipate that DexCom, Inc. will post 2.46 EPS for the current fiscal year.

DexCom Profile

DexCom, Inc is a medical device manufacturing company, which engages in the design, development and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6 CGM System, DexCom G6 CGM System for Medicare, Software and Mobile apps. The company was founded by John F.

Read More: How does the Federal Reserve determine interest rates?

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM).

Institutional Ownership by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.